Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

TVTX Company Profile and Key Details

NASDAQ : TVTX

Travere Therapeutics, Inc.

$19.73
0.6+314.00%
At Close 4:00 PM
62.72
BESG ScoreESG Rating

TVTX Stock Price Chart

Stock Price Today

Travere Therapeutics, Inc. (TVTX) stock surged +313.64%, trading at $19.73 on NASDAQ, up from the previous close of $19.13. The stock opened at $19.26, fluctuating between $18.86 and $19.87 in the recent session.

Stock Snapshot

19.13
Prev. Close
19.26
Open
1.75B
Market Cap
88.74M
Number of Shares
18.86
Day Low
19.87
Day High
-4.85
P/E Ratio
98.5%
Free Float in %
-4.07
EPS (TTM)
2.63
Book Value
-4.21
Cash Flow per Share
1.08M
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Mar 14, 202519.2619.8718.8619.731.14M
Mar 13, 202519.3119.6118.7919.131.78M
Mar 12, 202518.6619.6318.6619.271.56M
Mar 11, 202517.9018.6717.7118.131.36M
Mar 10, 202517.7618.1017.1517.871.84M
Mar 07, 202518.8119.3618.0418.091.84M
Mar 06, 202518.8719.4318.6318.941.12M
Mar 05, 202519.3519.7318.9119.411.33M
Mar 04, 202519.5820.0119.2019.701.95M
Mar 03, 202521.4421.9819.6019.801.49M
Feb 28, 202520.6521.4620.4721.402M
Feb 27, 202521.0921.4720.6320.641.02M
Feb 26, 202521.1721.9320.7721.031.55M
Feb 25, 202521.5821.7820.3920.652.68M
Feb 24, 202522.0622.0620.5721.231.7M
Feb 21, 202521.5022.9021.0021.983.09M
Feb 20, 202523.3723.6923.1423.581.33M
Feb 19, 202522.5423.4622.5023.331.46M
Feb 18, 202523.0023.3322.4822.661.4M
Feb 14, 202524.0024.1422.8222.911.47M

Contact Details

San Diego, CA 92130

United States

Website: https://www.travere.comContact: 888 969 7879

About Company

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Company Information

Employees385
Beta0.75
Sales or Revenue$145.24M
5Y Sales Change%-0.519%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Travere Therapeutics, Inc. (TVTX) stock price?
Travere Therapeutics, Inc. (NASDAQ: TVTX) stock price is $19.73 in the last trading session. During the trading session, TVTX stock reached the peak price of $19.87 while $18.86 was the lowest point it dropped to. The percentage change in TVTX stock occurred in the recent session was 3.14% while the dollar amount for the price change in TVTX stock was $0.60.
TVTX's industry and sector of operation?
The NASDAQ listed TVTX is part of Biotechnology industry that operates in the broader Healthcare sector. Travere Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of TVTX?
Dr. William E. Rote Ph.D.
Senior Vice President of R&D
Mr. Christopher Cline C.F.A., CFA
Chief Financial Officer
Mr. Peter Heerma
Chief Commercial Officer
Ms. Charlotte Smith
Senior Vice President of Public Affairs
Dr. Jula Inrig M.D.
Chief Medical Officer
Mr. Casey Logan
Senior Vice President of Corporation & Bus. Devel.
Ms. Angela Giannantonio
Senior Vice President of HR
Ms. Sandra Calvin
SVice President, Corporation Controller & Chief Accounting Officer
Dr. Noah L. Rosenberg M.D.
Executive Advisor
Ms. Elizabeth E. Reed
Senior Vice President, Gen. Counsel & Corporation Sec.
Dr. Eric M. Dube Ph.D.
Pres, Chief Executive Officer & Director
How TVTX did perform over past 52-week?
TVTX's closing price is 285.35% higher than its 52-week low of $5.12 where as its distance from 52-week high of $25.29 is -21.98%.
How many employees does TVTX have?
Number of TVTX employees currently stands at 385.
Link for TVTX official website?
Official Website of TVTX is: https://www.travere.com
How do I contact TVTX?
TVTX could be contacted at phone 888 969 7879 and can also be accessed through its website. TVTX operates from 3611 Valley Centre Drive, San Diego, CA 92130, United States.
How many shares of TVTX are traded daily?
TVTX stock volume for the day was 1.08M shares. The average number of TVTX shares traded daily for last 3 months was 1.59M.
What is the market cap of TVTX currently?
The market value of TVTX currently stands at $1.75B with its latest stock price at $19.73 and 88.74M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph